1st approved Symbicort generic, Breyna, now available in US
WEBAug 7, 2023 · The inhaled medication — the first Symbicort generic to be approved by the U.S. Food and Drug Administration — will become immediately available to eligible patients.. Like Symbicort, Breyna is approved as a maintenance therapy to lower airflow obstruction and prevent exacerbations in people with COPD, and for asthma patients, ages 6 …
Low-dose Morphine Improves Health in COPD Patients With …
WEBSep 3, 2020 · by Steve Bryson, PhD September 3, 2020. Regular, low-dose oral morphine led to significant health improvements in adults with advanced chronic obstructive pulmonary disease (COPD) who regularly experienced shortness of breath, according to results of a Phase 4 clinical trial. Treatment with morphine did …
COPD Trial Shows Breztri Aerosphere Significantly Reduces...
WEBby Joana Carvalho, PhD June 30, 2020. Breztri Aerosphere, AstraZeneca ’s triple combination therapy for chronic obstructive pulmonary disease (COPD), significantly reduces the frequency of moderate or severe exacerbations, compared to dual combination therapies, in patients with moderate to very severe forms of …
LupinHaler, generic version of Spiriva HandiHaler, available in US
WEBAug 28, 2023 · In Europe, generics of Boehringer Ingelheim’s Spiriva HandiHaler began launching in 2021, including ones from Glenmark Pharmaceuticals and Phargentis, but these medications haven’t become available in the U.S.. COPD is a chronic lung disease wherein the airways become blocked, leading to progressively worsening disease symptoms that include shortness of breath and wheezing.
Yupelri vs Spiriva: Similar benefits seen in Phase 4 COPD trial
WEBJan 8, 2024 · Yupelri (revefenacin) is not superior to Spiriva (tiotropium) at improving lung function in adults with severe chronic obstructive pulmonary disease (COPD), according to data from a Phase 4 clinical trial. The head-to-head study, called PIFR-2 (NCT05165485) and sponsored by Yupelri’s co-developers Theravance Biopharma …
Trelegy Ellipta Reduces COPD Exacerbations and Improves Lung …
WEBApr 24, 2018 · Results revealed that treatment with the triple therapy Trelegy Ellipta significantly reduced the number of COPD hospitalizations due to severe exacerbations by 34% compared to Anoro Ellipta. Compared to Breo Ellipta, the reduction was of 13%, but this difference was not statistically significant. The …
Zephyr Valve Boosts Lung Function, Life Quality for COPD Patients:...
WEBMay 27, 2021 · The Zephyr Endobronchial Valve significantly improved lung function and quality of life for at least two years in people with emphysema, a severe form of chronic obstructive pulmonary disease (COPD), according to new clinical trial data. “These long-term data further demonstrate that our Zephyr Valve is a safe, effective, and lasting ...
Spiolto Respimat Fares Well in Comparison with Spiriva Respimat
WEBApr 10, 2018 · The 52-week, Phase 3 DYNAGITO trial (NCT02296138) primarily tested whether Spiolto Respimat reduces the annualized rate of moderate and severe exacerbations beyond the benefits provided by Spiriva Respimat, which contains only the LAMA tiotropium.Scientists recruited COPD patients who had at least one moderate or severe exacerbation needing treatment with systemic glucocorticoids and/or ...
COPD Maintenance Treatment Breztri Aerosphere Approved by FDA
WEBJul 28, 2020 · The FDA’s approval was based on data from the Phase 3 clinical trial ETHOS (NCT02465567), conducted at some 740 sites worldwide.The trial was sponsored by Pearl Therapeutics, which was acquired by AstraZeneca in 2013.. ETHOS enrolled more than 8,500 people with COPD who had experienced at least one moderate-to-severe exacerbation in the year before the trial and had been given at least two ...
COPD trial of Breztri Aerosphere and cardiopulmonary risk opens
WEBMar 18, 2024 · The THARROS study (NCT06283966) is expected to enroll up to 5,000 COPD patients, ages 40 to 80, with a risk of cardiopulmonary complications at more than 650 centers in the U.S., Canada, and countries in Europe, South America, and Asia.. Participants will be randomly assigned to receive either Breztri Aerosphere or to AstraZeneca’s dual-combination Bevespi Aerosphere (glycopyrronium ...